Kernicterus: Everything You Need to Know

What is Kernicterus?

Kernicterus is a rare but serious type of brain damage that can occur in newborn infants when high levels of bilirubin (a yellow pigment produced by the breakdown of red blood cells) cross the blood‑brain barrier and deposit in the basal ganglia and other brain structures. The condition is sometimes called “bilirubin encephalopathy.” While mild elevations of bilirubin cause the common newborn “jaundice,” kernicterus represents the extreme end of the spectrum and can lead to permanent neurological deficits, hearing loss, vision problems, and even death if not recognized and treated promptly.

In most industrialized countries the incidence of kernicterus has dropped dramatically thanks to universal newborn screening for jaundice and early treatment with phototherapy. Nevertheless, it remains a concern in low‑resource settings and in certain high‑risk populations.

Common Causes

Kernicterus is not a disease itself; it is a complication of severe hyperbilirubinemia. The most frequent underlying conditions that raise bilirubin to dangerous levels include:

• Hemolytic disease of the newborn (HDN) – often due to ABO or Rh incompatibility.
• Breastfeeding‑related jaundice – inadequate milk intake or delayed lactation can increase bilirubin.
• Genetic enzyme deficiencies – most notably glucose‑6‑phosphate dehydrogenase (G6PD) deficiency and hereditary spherocytosis.
• Crigler‑Najjar syndrome type I – a rare autosomal‑recessive disorder causing absent bilirubin‑UGT enzyme activity.
• Physiologic newborn jaundice – the normal rise in bilirubin during the first week of life, which can become severe in preterm infants.
• Late‑onset sepsis or infection – infections increase hemolysis and impair bilirubin conjugation.
• Birth asphyxia or hypoxic‑ischemic injury – reduces hepatic blood flow and bilirubin metabolism.
• Internal hemorrhage (e.g., cephalo‑hematoma) – breakdown of blood in tissues releases additional bilirubin.
• Medications that displace bilirubin – such as sulfonamides, certain antibiotics, or non‑steroidal anti‑inflammatory drugs.
• Rare metabolic disorders – e.g., Gilbert’s syndrome or Dubin‑Johnson syndrome (usually milder, but can contribute).

Associated Symptoms

When bilirubin begins to affect the central nervous system, a constellation of neurologic and systemic signs may appear. These symptoms often evolve rapidly:

• Severe, prolonged jaundice (yellowing of the skin and sclera) persisting beyond 2–3 days in term infants or 5–7 days in preterm infants.
• Lethargy or decreased responsiveness.
• High‑pitched “cry” that is difficult to console.
• Hypotonia (floppy‑baby appearance) progressing to hypertonia or opisthotonus (arch‑back).
• Feeding difficulties or poor weight gain.
• Seizures of any type (tonic‑clonic, focal, or subtle).
• Auditory deficits – infants may not startle at loud noises.
• Movement disorders later in life (cerebral palsy‑like picture, choreoathetosis).
• Vision problems, such as nystagmus or difficulty tracking objects.

When to See a Doctor

Timely evaluation is critical. Parents or caregivers should contact a pediatrician or go to the emergency department if any of the following are observed:

• Jaundice that spreads to the abdomen, chest, or limbs, especially if it appears in the first 24 hours of life.
• Yellowing of the baby’s skin after the baby is 3 days old (term) or 5 days old (preterm).
• Any change in the baby’s level of alertness—excessive sleepiness, difficulty waking, or irritability.
• Feeding problems: refusing feeds, vomiting, or inability to gain weight.
• High‑pitched crying that does not stop with soothing.
• Muscle stiffness, limpness, or abnormal movements.
• Signs of dehydration (dry mouth, sunken fontanelle, decreased urine output).

When in doubt, seek care immediately – the risk of permanent damage rises quickly as bilirubin climbs.

Diagnosis

Diagnosing kernicterus involves both clinical assessment and laboratory testing:

1. Physical Examination

• Assessment of skin and scleral icterus intensity (using the “yellow light” method).
• Neurologic exam for tone, reflexes, and level of consciousness.
• Evaluation for hemolysis signs (e.g., pallor, splenomegaly).

2. Laboratory Tests

• Serum total bilirubin (STB) – the key marker. Levels >20 mg/dL (≈340 µmol/L) in term infants are high‑risk; lower thresholds apply for preterm infants.
• Direct (conjugated) vs. indirect (unconjugated) bilirubin fraction – kernicterus is linked to markedly elevated indirect bilirubin.
• Complete blood count, reticulocyte count, and peripheral smear – to detect hemolysis.
• Blood type and Coombs test – to identify ABO/Rh incompatibility.
• G6PD activity assay when deficiency is suspected.
• Liver function tests if cholestasis is a concern.

3. Imaging & Neurophysiology

• Brain MRI may show hyperintensity in the basal ganglia, but it is usually reserved for later confirmation.
• Amplitude‑integrated EEG (aEEG) or conventional EEG can detect seizure activity.
• Auditory brainstem response (ABR) testing for early hearing loss.

4. Scoring Systems

Clinicians often use the “Bhutani nomogram” (bilirubin‑age chart) to determine the risk zone (low, intermediate, high) and decide on treatment thresholds (American Academy of Pediatrics guidelines).

Treatment Options

Therapy focuses on rapidly reducing serum bilirubin, preventing further brain uptake, and managing complications.

1. Phototherapy

• First‑line treatment for bilirubin >15 mg/dL in term infants or lower thresholds in preterm infants.
• Blue‑light (460–490 nm) converts bilirubin into water‑soluble isomers that can be excreted without conjugation.
• Continuous double‑surface phototherapy is most effective; fiber‑optic blankets are an alternative for home use.

2. Exchange Transfusion

• Indicated when bilirubin rises rapidly despite maximal phototherapy or when levels exceed 25 mg/dL (≈425 µmol/L) in term infants.
• Blood is removed and replaced with donor plasma, rapidly lowering bilirubin and treating hemolysis.
• Requires a neonatal intensive care unit (NICU) and experienced personnel; risks include electrolyte shifts, infection, and thrombocytopenia.

3. Intravenous Immunoglobulin (IVIG)

• Used primarily for immune‑mediated hemolysis (e.g., Rh incompatibility) to reduce the need for exchange transfusion.
• Administered as a 1 g/kg infusion over 2 hours; may be repeated.

4. Supportive Care

• Ensure adequate hydration and caloric intake – frequent feeds or supplemental IV fluids.
• Monitor temperature, urine output, and weight closely.
• Seizure management with phenobarbital or other anticonvulsants if needed.

5. Long‑Term Rehabilitation

• Physical, occupational, and speech therapy for motor or developmental delays.
• Early intervention programs and audiology follow‑up for hearing impairment.
• Neuro‑psychology assessment for cognitive sequelae.

Prevention Tips

Most cases of kernicterus are preventable with early detection and management of newborn jaundice.

• Universal bilirubin screening – Measure total serum bilirubin before discharge (typically 24–48 hours after birth).
• Educate caregivers – Teach parents to recognize yellow skin, dark urine, poor feeding, or increased sleepiness.
• Promote early and frequent breastfeeding – Initiate within the first hour of life and aim for at least 8–12 feeds per day.
• Identify high‑risk groups – Preterm infants, those with known blood‑type incompatibility, G6PD deficiency, or a family history of bilirubin disorders.
• Ensure appropriate follow‑up – Arrange bilirubin check‑ups at 48 hours and again before discharge for at‑risk newborns.
• Avoid medications that displace bilirubin – Discuss any drug use with the pediatrician, especially sulfonamides and certain antibiotics.
• Maintain a warm, well‑hydrated environment – Prevent dehydration, a common precipitant of higher bilirubin levels.

Emergency Warning Signs

If any of the following appear, seek emergency medical care immediately (call 911 or go to the nearest emergency department):

• Sudden worsening of jaundice, especially if the skin turns deep yellow or orange.
• Extreme lethargy or unresponsiveness.
• Persistent high‑pitched crying that cannot be soothed.
• Seizures or abnormal jerking movements.
• Muscle rigidity, arching of the back, or floppy‑baby appearance.
• Signs of dehydration – sunken fontanelle, dry mouth, few wet diapers (< 3 in 24 hrs).
• Rapid weight loss (> 5 % of birth weight in 24 hrs).

Key Take‑aways

Kernicterus is a preventable, life‑threatening complication of severe neonatal jaundice. Early recognition of high bilirubin levels, prompt use of phototherapy, and close follow‑up are the cornerstones of prevention. When warning signs appear, immediate medical attention can make the difference between full recovery and permanent neurological injury.